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LEGAL AND ETHICAL IMPLICATIONS OF 
CRISPR APPLICATIONS IN PSYCHIATRY* 
ALEXANDRA L. FOULKES,** TAKAHIRO SODA,*** MARTILIAS 
FARRELL,**** PAOLA GIUSTI-RODRÍGUEZ,***** GABRIEL LÁZARO-
MUÑOZ****** 
Gene-environment interactions play a key role in how psychiatric 
disorders manifest and develop. Psychiatric genetics researchers 
are making progress in identifying genomic correlates of many 
disorders. And recently, the field of genetics has given rise to a 
technology that many claim will revolutionize the biological 
sciences and propel the field into a transformative phase: the 
powerful gene-editing tool known as CRISPR-Cas9. This Article 
illustrates which psychiatric conditions are likely to make 
attractive targets for CRISPR as the technology evolves and 
CRISPR therapies become viable tools to manage or prevent 
disorders in a clinical setting. We examine the potential scientific 
and clinical challenges of applying CRISPR in the mental health 
context, along with the regulatory, ethical, and legal issues that 
might arise as a consequence of these applications. 
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INTRODUCTION 
Treating psychiatric disorders with the drugs and therapies 
developed to date has proved challenging. Psychotropic medications 
often aren’t effective for patients,1 who in turn have a hard time 
committing to rigorous and slow-acting treatment regimens.2 But in 
addition to being notoriously hard to treat, psychiatric disorders are 
also well known for being highly heritable.3 As such, a number of 
recent large-scale genetic studies have focused their efforts on 
psychiatric disorders,4 and this innovative research has begun to 
unravel the science behind important genes and causal pathways.5 
Breakthroughs in genetics have made room for a potentially superior 
treatment option: the future application of gene-editing technologies 
for addressing the symptoms of psychiatric disorders.6 
Ever since the elegant discovery of the double helix in 1953,7 
scientists have looked for ways to manipulate and design DNA.8 As a 
consequence, gene-editing tools have actually been around for some 
time.9 Yet it wasn’t until the advent of “a simple, inexpensive, and 
 
 1. See Anita Kablinger, Treatment Resistance: Challenges and Solutions, 
PSYCHIATRIC TIMES (Sept. 1, 2007), http://www.psychiatrictimes.com/articles/treatment-
resistance-challenges-and-solutions [https://perma.cc/R6NZ-UJXR]. 
 2. See, e.g., Annette Zygmunt et al., Interventions to Improve Medication Adherence 
in Schizophrenia, 159 AM. J. PSYCHIATRY 1653, 1653 (2002) (“Rates of medication 
nonadherence among outpatients with schizophrenia have been found to approach 50% 
during the first year after hospital discharge. The actual rate of nonadherence may be even 
higher .	.	.	.” (footnotes omitted)). 
 3. Michael J. Gandal et al., The Road to Precision Psychiatry: Translating Genetics 
into Disease Mechanisms, 19 NATURE NEUROSCIENCE 1397, 1397 (2016). 
 4. See id. (discussing “more recent, large-scale genome-wide studies” of psychiatric 
diseases). 
 5. Id.  
 6. See Tom Ulrich, Gene Sifting for Gene Snipping: GWAS as a Source of Gene 
Editing Targets, VECTOR (Oct. 29, 2015), https://vector.childrenshospital.org/2015/10/
gwas-as-a-source-of-gene-editing-targets/ [http://perma.cc/CT8P-GTF2]; see also Roni 
Dengler, Major Mental Illnesses Unexpectedly Share Brain Gene Activity, Raising Hope for 
Better Diagnostics and Therapies, SCIENCE (Feb. 8, 2018, 2:00 PM), 
https://www.sciencemag.org/news/2018/02/major-mental-illnesses-unexpectedly-share-brain-
gene-activity-raising-hope-better [https://perma.cc/EJ8D-D484]. 
 7. See generally J. D. Watson & F. H. C. Crick, Molecular Structure of Nucleic Acids: 
A Structure for Deoxyribose Nucleic Acid, 171 NATURE 737 (1953) (describing the 
authors’ discovery of the structure of DNA).  
 8. See Brian Colwell, Biotechnology Timeline: Humans Have Manipulated Genes 
Since the ‘Dawn of Civilization,’ GENETIC LITERACY PROJECT (July 18, 2017), 
https://geneticliteracyproject.org/2017/07/18/biotechnology-timeline-humans-manipulating-
genes-since-dawn-civilization/ [http://perma.cc/NJ43-9XHM]. 
 9. See Jennifer A. Doudna & Emmanuelle Charpentier, The New Frontier of 
Genome Engineering with CRISPR-Cas9, 346 SCIENCE, no. 1258096, Nov. 28, 2014, at 1, 1, 
2 fig.1. 
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remarkably effective genome engineering method”—known as 
CRISPR-Cas9 (“CRISPR”)10—that biology was propelled into a 
transformative phase: CRISPR triggered a revolution.11  
CRISPR stands for Clustered Regularly Interspaced Short 
Palindromic Repeats12 and works like a pair of molecular scissors.13 
Scientists can direct CRISPR to a specific spot along an individual’s 
DNA and have the molecular scissors make cuts in the gene 
sequence.14 Therapeutically relevant changes can then be inserted.15 
As clinical trials using CRISPR systems to target specific conditions 
are slated to start around the world, a debate has sparked on the legal 
and ethical implications of CRISPR technology.16 Certainly, a 
prudent look to the potential niches in psychiatry where CRISPR 
systems may prove useful requires giving some attention to the legal 
and ethical issues that might arise. This is particularly so given the 
incendiary past of the American legal discourse on the intersection of 
psychiatric disorders and genetic modification.17 
This Article argues that while applications of CRISPR in 
psychiatry may not be imminent, these applications are no longer 
improbable hypotheticals. And where applications in psychiatry may 
well exist in the near future, there are important legal and ethical 
concerns that warrant careful consideration. This Article will proceed 
in three parts. Part I serves as an overview of CRISPR technologies, 
 
 10. David Baltimore et al., A Prudent Path Forward for Genomic Engineering and 
Germline Gene Modification, 348 SCIENCE 36, 36 (2015). Although the terms CRISPR-
Cas9 and CRISPR are used interchangeably, CRISPR-Cas9 is a system that incorporates 
“CRISPR,” which are the repeat sequences frequently observed in single-celled 
organisms. See Questions and Answers About CRISPR, BROAD INST., 
https://www.broadinstitute.org/what-broad/areas-focus/project-spotlight/questions-and-
answers-about-crispr [https://perma.cc/LM4S-MG92]. 
 11. See Doudna & Charpentier, supra note 9, at 1. 
 12. DAVID P. CLARK & NANETTE J. PAZDERNIK, MOLECULAR BIOLOGY 573 (2d ed. 
2013).  
 13. See Andrea Ramirez, Editing the Book of Life with Molecular Scissors, NIH: 
NAT’L HUM. GENOME RES. INST. (Apr. 3, 2013), https://www.genome.gov/27553432/
editing-the-book-of-life-with-molecular-scissors/ [http://perma.cc/R2HJ-5R77]. The Cas9 
in CRISPR-Cas9 refers to certain genes that are associated with important repeated 
sequences, known as Cas genes. Cas genes, including Cas9 genes, produce the nuclease 
scissor proteins that scientists have used to design genome-editing tools that cut into 
human DNA. This is explained in more detail below. See infra Section I.A. 
 14. See Ramirez, supra note 13. 
 15. See id.  
 16. See, e.g., E. Rodriguez, Ethical Issues in Genome Editing Using CRISPR/Cas9 
System, 7 J. CLINICAL RES. & BIOETHICS, no. 1000266, Mar. 24, 2016, at 1, 2–3. 
 17. For example, in Buck v. Bell, 274 U.S. 200 (1927), Justice Holmes concluded with 
the unfortunate remark: “Three generations of imbeciles are enough.” Id. at 207. For a 
short description of the facts and holding of Buck, see infra note 150. 
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skimming the surface of the relevant science, placing CRISPR 
systems in their historical context, and evaluating regulatory 
frameworks currently in place. Part II focuses on CRISPR and its 
potential uses in psychiatry, identifying where the technology might 
be most immediately applied. Part III addresses the legal, ethical, and 
policy challenges that arise from the application of CRISPR in a 
psychiatric context. 
I.  CRISPR TECHNOLOGIES: AN OVERVIEW 
A. A Brief Introduction to the Science 
DNA serves as a blueprint for all of an organism’s characteristics 
and traits after birth: it is the instructions—a set of plans—for 
building a body.18 A chain of DNA is made up of building blocks, 
small molecules called nucleotides.19 These nucleotides string 
together to form different sequences that code for certain messages, 
and these different message sequences are referred to as genes.20 The 
sum total of an individual’s DNA—the collection of all of a person’s 
genes—is referred to as a genome.21 Scientists have been modifying 
organisms’ genomes for some time, and recently these technologies 
have become highly effective.22 
To understand gene-editing technologies, it’s helpful to have a 
grasp on how scientists cut and repair DNA. Nuclease is a protein23 
 
 18. RICHARD DAWKINS, THE SELFISH GENE 23 (1976). Although a simple way to 
understand DNA, if taken literally this analogy is not precise. Genes alone do not serve as 
a blueprint, but rather the genetic blueprint has downstream effects, such as the 
interactions between different genes, that ultimately dictate how a body develops. See 
Bora Zivkovic, BIO101—From Genes to Traits: How Genotype Affects Phenotype, SCI. 
AM.: BLOG AROUND THE CLOCK (Sept. 17, 2011), https://blogs.scientificamerican.com/
a-blog-around-the-clock/bio101-from-genes-to-traits-how-genotype-affects-phenotype 
[http://perma.cc/8CN4-4FRH].  
 19. DAWKINS, supra note 18, at 23. There are only four different nucleotides that 
make up DNA: Adenine, Thymine, Cytosine, and Guanine. See id. For an accessible 
explanation of the building blocks of DNA, see Bozeman Science, What Is DNA?, 
YOUTUBE (Dec. 7, 2011), https://www.youtube.com/watch?v=q6PP-C4udkA 
[http://perma.cc/Q8JF-4H5N]. 
 20. See DNA, Genes and Chromosomes, U. LEICESTER, https://www2.le.ac.uk/projects/
vgec/highereducation/topics/dna-genes-chromosomes [https://perma.cc/7YPE-B5CE]. 
 21. What Is a Genome?, NIH: GENETICS HOME REFERENCE, https://ghr.nlm.nih.gov/
primer/hgp/genome [http://perma.cc/B5PJ-54R5] (last updated Apr. 30, 2019).  
 22. See Baltimore et al., supra note 10, at 36. 
 23. All proteins are the product of gene sequences. For a quick and accessible 
explanation of protein synthesis, see Yourgenome, From DNA to Protein—3D, YOUTUBE 
(Jan. 7, 2015), https://www.youtube.com/watch?v=gG7uCskUOrA [http://perma.cc/5QY6-
T3GQ]. 
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that functions like the equivalent of molecular scissors.24 Scientists 
can direct nuclease scissors to an exact spot among the billions of 
nucleotides making up a DNA sequence, and the nuclease will cut out 
a part of the DNA chain.25 This cut can be repaired by either allowing 
the loose ends to join back together or by having the CRISPR system 
insert a new designer DNA segment to replace the piece cut out by 
the nuclease.26 
Thanks to advances in DNA sequencing and genome-wide 
association studies (“GWAS”),27 scientists now have more 
information about which DNA segments influence the development 
of disease.28 The information gathered by GWAS can be applied 
through CRISPR technologies. As previously noted, CRISPR stands 
for Clustered Regularly Interspaced Short Palindromic Repeats.29 
These repeats are distinct sequences of nucleotides, frequently 
observed in the DNA of single-celled organisms like bacteria.30 
Certain genes are associated with these repeated sequences, and these 
genes are known as Cas genes.31 Cas genes, including the Cas9 gene, 
produce the nuclease scissor proteins (“Cas proteins”) that scientists 
use to design genome-editing tools that cut into human DNA.32  
The Cas protein is one of two main components making up an 
engineered CRISPR system.33 The second is known as a guide RNA. 
A guide RNA is a short synthetic RNA sequence that includes a 
 
 24. See Ramirez, supra note 13. 
 25. Id. We have simplified the description of the process so as to make it more 
accessible to a broader audience. The science behind CRISPR’s mechanisms is much more 
complicated, and the excision language we have employed is far too cursory to adequately 
convey the nuances involved. Most of the time, CRISPR nucleases either make a double-
stranded break or a nick in one strand. An excision needs two breaks, and even then, the 
excision really isn’t a result of the molecular scissors: it’s the DNA repair machinery 
deleting the intervening DNA. For a detailed explanation of CRISPR mechanisms as 
currently understood, see generally Samuel H. Sternberg & Jennifer A. Doudna, 
Expanding the Biologist’s Toolkit with CRISPR-Cas9, 58 MOLECULAR CELL 568 (2015). 
 26. Ramirez, supra note 13. 
 27. In GWAS, scientists look at the genomes of a large number of afflicted individuals 
and find small variations that occur repeatedly in the genes of these individuals but don’t 
appear in the genomes of nonafflicted individuals. See Genome-Wide Association Studies 
Fact Sheet, NIH: NAT’L HUM. GENOME RES. INST. (Aug. 27, 2015), 
https://www.genome.gov/20019523/ [http://perma.cc/DQ5J-ABG5]. 
 28. See Baltimore et al., supra note 10, at 36. 
 29. CLARK & PAZDERNIK, supra note 12, at 573.  
 30. Id. 
 31. Philippe Horvath & Rodolphe Barrangou, CRISPR/Cas, the Immune System of 
Bacteria and Archaea, 327 SCIENCE 167, 167 (2010).  
 32. See id.  
 33. CRISPR Guide, ADDGENE, https://www.addgene.org/crispr/guide/ [http://perma.cc/
X6A6-93AL]. 
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sequence necessary for Cas-binding—a scaffold sequence—and a 
user-defined sequence that directs the CRISPR system to its genomic 
target.34 This means one can change the genomic target of the Cas 
protein by simply changing the guide RNA’s protein sequence. 
Although CRISPR is the most effective and accessible method of 
genetic engineering available today, CRISPR was not the first gene-
editing tool developed.35 Other technologies targeting similar goals 
have been around for several decades.36 Yet CRISPR is being 
championed as a technique that promises to revolutionize medicine 
where previous attempts have failed.37 Technologies such as zinc 
finger nucleases (“ZFNs”), Transcription Activator-Like Effector 
Nucleases (“TALENs”), and mega-nucleases have seen some 
success.38 But these technologies have yet to alter the landscape of 
modern medicine in the way CRISPR proponents have promised.39 
B. CRISPR’s Precursors: Previous Attempts at Achieving the Same 
Functionality 
Gene-editing tools that predate CRISPR all share the same 
mechanism of action—they are all nucleases that create breaks at 
specific locations in DNA.40 The most important characteristic of a 
nuclease, as it relates to medical gene editing, is the programmability 
of the molecular scissors41—that is, the relative ease with which 
scientists can design and produce a molecular scissor that will cut the 
 
 34. Id. “RNA is one of the three major biological macromolecules that are essential 
for all known forms of life (along with DNA and proteins).” What Is RNA?, RNA SOC’Y, 
https://www.rnasociety.org/about/what-is-rna/ [http://perma.cc/6FYH-YHP6]. 
 35. See Doudna & Charpentier, supra note 9, at 1. In essence, “gene editing” connotes 
the use of a tool that can alter or even correct DNA and has effectively come to succeed 
the term “genetic engineering.” John J. Mulvihill et al., Ethical Issues of CRISPR 
Technology and Gene Editing Through the Lens of Solidarity, 122 BRIT. MED. BULL. 17, 
18 (2017). 
 36. See Doudna & Charpentier, supra note 9, at 1.  
 37. See, e.g., Jacob S. Sherkow, CRISPR, Patents, and Public Health, 90 YALE J. 
BIOLOGY & MED. 667, 667 (2017) (“CRISPR has the potential to revolutionize 
medicine.”). 
 38. See Doudna & Charpentier, supra note 9, at 1. 
 39. See id.  
 40. See Rasmus O. Bak, Natalia Gomez-Ospina & Matthew H. Porteus, Gene Editing 
on Center Stage, 34 TRENDS GENETICS 600, 600 (2018). 
 41. See Tuhin Kumar Guha, Alvan Wai & Georg Hausner, Programmable Genome 
Editing Tools and Their Regulation for Efficient Genome Engineering, 15 
COMPUTATIONAL & STRUCTURAL BIOTECHNOLOGY J. 146, 147 (2017) (addressing the 
importance of programmability, given that “[o]ne crucial concern when applying these 
genetic editing tools is the potential of cleavage at non-targeted sites,” which “can be 
lethal or generate undesirable mutations”).  
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DNA at the desired location.42 To place the utility of CRISPR in 
some context, two of CRISPR’s precursors are described here in 
detail: ZFNs and TALENs. 
ZFNs are one of the earliest popularized attempts at site-specific 
nuclease targeting.43 Researchers combine the scissor component 
found in one protein, nonspecific FokI endonuclease domain,44 and 
the DNA-targeting component of another protein, a zinc finger 
protein, to create programmable DNA scissors.45 Zinc fingers get 
their name from a particular sequence of amino acids. When these 
amino acids come together with a zinc ion, they can bind to a specific 
sequence of DNA three basepairs long.46 To target a longer DNA 
segment, scientists put more zinc fingers together. For example, 
targeting eighteen basepairs of DNA would require six zinc fingers. 
In order to target any particular DNA sequence, researchers had 
to develop a zinc finger for each of the sixty-four possible DNA 
basepair triplets.47 Because of these complexities and others, creation 
of ZFN constructs has proven difficult.48 Despite the associated 
challenges, ZFNs are some of the oldest and most studied designer 
nucleases available and are the focus of recent clinical trials.49 
TALENs use the same architecture as ZFNs. With TALENs, the 
scissor component is fused with a different type of DNA-binding 
component: the transcription activator-like effector (“TALE”).50 
These DNA-binding elements are different from zinc fingers in that 
their DNA-binding domains each recognize a single basepair of 
 
 42. See id.; see also Srinivasan Chandrasegaran & Jeff Smith, Chimeric Restriction 
Enzymes: What Is Next?, 380 BIOLOGICAL CHEMISTRY 841, 847 (1999) (“Many of the 
difficulties associated with gene therapy are likely to be overcome if one could insert the 
corrected version of the mutation at the precise location of the genetic defect within the 
genome .	.	.	. Current gene therapy vectors lack the requisite sequence specificity necessary 
for the targeted correction of the defective site within the genome.”).  
 43. See James Gallagher, First Gene-Editing in Human Body Attempt, BBC NEWS 
(Nov. 16, 2017), https://www.bbc.com/news/health-42009929 [http://perma.cc/C34W-P93G] 
(discussing the first attempt at gene editing in human cells, which was done using ZFNs). 
 44. See Chandrasegaran & Smith, supra note 42, at 843.  
 45. Id. at 844.  
 46. Id. at 843 (“[E]ach finger interacts with a base pair triplet within the DNA 
substrates.”).  
 47. See id.  
 48. See Doudna & Charpentier, supra note 9, at 1.  
 49. See, e.g., Ascending Dose Study of Genome Editing by Zinc Finger Nuclease 
Therapeutic SB-FIX in Subjects with Severe Hemophilia B, CLINICALTRIALS.GOV, 
https://clinicaltrials.gov/ct2/show/NCT02695160 [http://perma.cc/CK2K-PTXX] (last updated 
Feb. 12, 2019). 
 50. Michelle Christian et al., Targeting DNA Double-Strand Breaks with TAL 
Effector Nucleases, 186 GENETICS 757, 757 (2010). 
97 N.C. L. REV. 1359 (2019) 
2019] CRISPR IN PSYCHIATRY 1367 
DNA,51 as opposed to the zinc fingers’ three basepairs. Thus, it is 
simpler to design a TALEN that recognizes a specific eighteen-
basepair sequence of DNA. Due to the nature of each DNA-binding 
element, however, TALENs are difficult to build using available 
molecular biology techniques—a technical hurdle that has stifled 
TALEN adoption.52 
In contrast, the CRISPR system provides a high degree of DNA 
sequence specificity and programmability.53 The relative ease of 
design and production of the CRISPR components is the primary 
feature that separates this system from its precursors and has caused a 
renewed interest and enthusiasm in medical gene editing. 
C. The Legal and Ethical Legacy of Previous Attempts and Their 
Implications 
Because CRISPR is not the first attempt at gene editing, at first 
blush, it seems as though many of the ethical issues raised by CRISPR 
are equivalent to those that surfaced several decades ago.54 Given the 
previous attempts at achieving therapeutic outcomes by means of 
gene editing, a vast body of literature exists addressing important 
legal and ethical issues that arise in the context of genetic 
modification.55 As such, a framework of general principles governing 
the rules for human gene editing already exists. This framework is 
worth considering as a foundation to any dialogue on the ethical 
implications of new gene-editing technologies.56 
Early gene-therapy clinical research resulted in serious adverse 
events.57 But it wasn’t until the death of Jesse Gelsinger, a young 
 
 51. See id. 
 52. See Thomas Gaj, Charles A. Gersbach & Carlos F. Barbas III, ZFN, TALEN, and 
CRISPR/Cas-Based Methods for Genome Engineering, 31 TRENDS BIOTECHNOLOGY 397, 
399 (2013).  
 53. See id. at 402.  
 54. See, e.g., Mulvihill et al., supra note 35, at 17–18 (“We see no new ethical issues, 
compared with gene therapy and genetic engineering in general, apart from the explosive 
rate of findings.”). 
 55. See Eric T. Juengst, Crowdsourcing the Moral Limits of Human Gene Editing?, 
HASTINGS CTR. REP., May–June 2017, at 15, 15 (“On the whole, [the Committee on 
Human Gene Editing’s] report [authored in response to the success of CRISPR/Cas9 
systems] builds reassuringly on what has come before and underscores that there are 
precedents, arguments, and well-accepted general principles to turn to in framing the 
‘rules’ for human gene editing.”).  
 56. See id. (“[T]he report also provides a great primer on the science and regulatory 
landscape of gene editing, and it reviews some of the key points from the debates over 
human germ-line and enhancement interventions to date.”).  
 57. See Theodore Friedmann, Principles for Human Gene Therapy Studies, 287 
SCIENCE 2163, 2163 (2000). Most notable is the death of eighteen-year-old Jesse Gelsinger 
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patient enrolled in a gene-therapy clinical trial, that a great number of 
these adverse events became public.58 Important, though not unique 
to gene editing, is the fact that preclinical data cannot reveal all 
possible adverse outcomes. And so, as with any highly experimental 
treatment involving severely ill patients, human trials yield 
unexpected and unintended results.59 The need for a more thorough 
understanding of the science and effects of the applications of gene 
editing in humans was criticized as a limitation of early technologies.60 
It remains a concern of the scientific community in the face of 
CRISPR’s clinical applications. 
It is critical that safety information regarding new technologies is 
made readily available.61 As early mishaps in gene-therapy clinical 
trials have taught us, the lack of public awareness of safety problems 
impairs not only the ability of researchers to inform subjects of 
potential risks but also their ability to design safe studies. That is, 
when clinical research sites fail to report adverse events, other 
research sites cannot adjust their protocols and informed consent 
 
who had been diagnosed with ornithine transcarbamylase deficiency. Id. Gelsinger is 
thought to have died as a result of an experimental gene-therapy clinical trial. Id. For a 
poignant account of Gelsinger’s death, see generally Paul L. Gelsinger, Uninformed 
Consent: The Case of Jesse Gelsinger, in LAW AND ETHICS IN BIOMEDICAL RESEARCH: 
REGULATION, CONFLICT OF INTEREST, AND LIABILITY 12 (Trudo Lemmens & Duff R. 
Waring eds., 2006).  
 58. LORI B. ANDREWS, MAXWELL J. MEHLMAN & MARK A. ROTHSTEIN, 
GENETICS: ETHICS, LAW AND POLICY 405–06 (2002). Due to a long-standing Food and 
Drug Administration (“FDA”) policy stating that adverse events are considered trade 
secrets and thereby need not be disclosed to the public, the adverse events that had been 
reported to the FDA were never disclosed. Id.; see also 21 C.F.R. §§	601.50–.51 (2018). But 
see id. §	601.50(c) (stating that “[n]otwithstanding the provisions of §	601.51, the [FDA] 
shall disclose upon request to an individual on whom an investigational biological product 
has been used a copy of any adverse reaction report relating to such use”). And since the 
NIH did have a policy to make public adverse events reported to the agency, investigators 
failed to report their findings. ANDREWS ET AL., supra, at 406. Only thirty-nine serious 
adverse events had been reported to the NIH before Gelsinger’s death. Id. Six hundred 
ninety-one reports streamed in afterward. Id.  
 59. See id. It is also important to note that scientists’ depth of understanding of the 
pharmacokinetics and mechanisms for gene-editing technologies does not match the 
understanding that usually accompanies a potential new drug. Id. That is, scientists usually 
know a lot more about a new pharmacological agent up for FDA approval than they know 
about the mechanisms at play when gene-editing technologies are applied. There is also 
the possibility that modifications intended to target somatic cells may have unintended 
effects on the germline, which poses implications for how to manage enrolling patients of 
reproductive age into clinical trials. See Nancy M.P. King, Accident & Desire: Inadvertent 
Germline Effects in Clinical Research, HASTINGS CTR. REP., Mar.–Apr. 2003, at 23, 23.  
 60. See generally Friedmann, supra note 57 (discussing the lessons learned from 
adverse gene therapy studies and “reexamin[ing] the principles that constitute the 
foundation of clinical research in gene therapy”).  
 61. See ANDREWS ET AL., supra note 58, at 406. 
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procedures based on the new information and may overlook 
important patterns in their patients’ reported side effects. Likewise, 
patients cannot have a full understanding of the risks and benefits the 
research entails.62 To safeguard against information deficiencies, 
commentators have proposed optimizing informed consent 
procedures to protect patient interests.63 Additionally, they have 
suggested that the monitoring of clinical trials needs improvement.64 
To be sure, previous attempts at genetic modification have 
generally underdelivered on lofty promises of profound benefits.65 
CRISPR technology, however, may finally find its way into the 
successful clinical applications that eluded all others. CRISPR is 
different: it’s cheaper, easier to use, and developing at a much faster 
pace than its technological predecessors.66 Also, its mechanism 
promises results that sound highly desirable: a simple process that can 
precisely target and cut out an undesirable mutation, replace it with a 
“normal” DNA sequence, and then zip the repaired DNA back up 
again.67 But the assumption that CRISPR can be used therapeutically 
oversimplifies and understates the complexities of translating basic 
scientific research into a clinical setting. As before, part of the ethical 
challenge accompanying the introduction of CRISPR technologies 
into a clinical setting is divorcing hype from reality.68 
We begin by identifying those areas of psychiatry in which 
CRISPR may find more immediate application and go on to address 
the legal and ethical implications unique to the applications of 
 
 62. See id. Incidentally, the FDA proposed a regulation that would have amended the 
biological licensing application and provided for the public disclosure of investigational 
new drug safety reports. See Availability for Public Disclosure and Submission to FDA for 
Public Disclosure of Certain Data and Information Related to Human Gene Therapy or 
Xenotransplantation, 66 Fed. Reg. 4688, 4688 (proposed Jan. 18, 2001). But the FDA 
eventually withdrew the proposed rule. See Withdrawal of Two Proposed Rules, 81 Fed. 
Reg. 79,400, 79,400 (Nov. 14, 2016) (withdrawing the proposed regulation because the 
FDA believed the concerns were outdated).  
 63. See, e.g., Friedmann, supra note 57, at 2163, 2165; see also Gail E. Henderson et 
al., Therapeutic Misconception in Early Phase Gene Transfer Trials, 62 SOC. SCI. & MED. 
239, 250–52 (2006) (proposing a novel method to manage the expectations of patients 
enrolling in early phase clinical trials and calling for investigators to describe the potential 
benefits of these trials realistically to patients who viewed them as their last hope). 
 64. Friedmann, supra note 57, at 2165. One of the most egregious findings of the 
FDA’s investigations of early gene therapy trials was the fact that the investigators had 
serious and undisclosed conflicts of interest. See ANDREWS ET AL., supra note 58, at 405. 
They owned stock in the biotechnology company trying to monetize the gene therapy. Id.  
 65. See Juengst, supra note 55, at 15.  
 66. Evita V. Grant, FDA Regulation of Clinical Applications of CRISPR-CAS Gene-
Editing Technology, 71 FOOD & DRUG L.J. 608, 632 (2016). 
 67. See supra Section I.A. 
 68. Mulvihill et al., supra note 35, at 19. 
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CRISPR in psychiatry.69 Certainly, clinical applications of CRISPR 
technology for psychiatric disorders are ultimately distant goals.70 
After all, even if scientists are successful at modifying every gene 
potentially associated with a psychiatric disorder, the intervention’s 
potential effects are still unknown. For example, even if genomes 
could be successfully edited to express the relevant proteins in 
nonpathogenic form, the impact of having lived years with pathogenic 
variants could have long-term downstream effects on the brain that 
limit the effectiveness of CRISPR interventions for reducing 
psychiatric symptoms.71 Nevertheless, engaging in dialogue on the 
potential ethical and legal issues that might arise as these applications 
approach clinical realization is essential for preparing the scientific 
community to responsibly engage in the execution of CRISPR 
applications. This is especially true in the field of psychiatry, given the 
egregious history that exists at the intersection of psychiatry and the 
law.72 
D. Regulating CRISPR: The Current Framework’s Structure and 
Consequences 
The enthusiasm for CRISPR and its possible applications are 
accompanied by questions as to how and to what extent the testing of 
CRISPR systems in humans should be regulated.73 The Food and 
Drug Administration (“FDA”), housed within the Department of 
Health and Human Services (“DHHS”), is tasked with regulating 
technologies relating to drugs and biological products in accordance 
 
 69. See infra Section II.B, Part III. 
 70. See infra Part II. 
 71. See infra notes 163–64 and accompanying text. 
 72. See infra Section III.B.2. 
 73. Robert M. Califf & Ritu Nalubola, FDA, FDA’s Science-Based Approach to 
Genome Edited Products, FDA VOICE (Jan. 18, 2017), https://perma.cc/X936-U9JJ, 
reprinted in Robert M. Califf & Ritu Nalubola, FDA’s Science-Based Approach to 
Genome Edited Products, CHECK ORPHAN (Jan. 19, 2017), http://www.checkorphan.org/
news/fda2019s-science-based-approach-to-genome-edited-products [https://perma.cc/C7H3-
QDG7]; see also Preetika Rana, Amy Dockser Marcus & Wenxin Fan, China, 
Unhampered by Rules, Races Ahead in Gene-Editing Trials, WALL ST. J. (Jan. 21, 2018, 
2:19 PM), https://www.wsj.com/articles/china-unhampered-by-rules-races-ahead-in-gene-
editing-trials-1516562360 [https://perma.cc/WZ4S-GQ3Q (dark archive)]. Clinical trials 
using CRISPR technologies are already underway in China, where the regulation and 
oversight of clinical trials is different than the oversight in the United States. See Rana et 
al., supra. Chinese clinicians stated that the potential benefit of CRISPR technologies 
outweigh the benefit of more rigorous regulations: “Dr. Wu says he sees saving patients’ 
lives as paramount. He began by testing [CRISPR] on three patients and has modified 
genes of more than a dozen. He says he is planning other trials with lung-cancer and 
pancreatic-cancer patients.” Id.  
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with the Federal Food, Drug, and Cosmetic Act of 1938,74 the Public 
Health Service Act of 1944,75 and their subsequent amendments.76 As 
with previous gene-editing tools, the FDA treats CRISPR in 
accordance with its 1998 guidance on human somatic cell therapy and 
gene therapy.77 Gene-therapy products, including CRISPR systems, 
are currently regulated under the existing framework for biological 
products.78 This means that CRISPR interventions have to undergo 
testing via clinical trials before obtaining FDA approval for clinical 
use.79 
Once a CRISPR compound is developed and information about 
its potential toxic effects is gathered via animal research, the sponsor 
of the CRISPR compound must submit an Investigational New Drug 
 
 74. Federal Food, Drug, and Cosmetic Act, ch. 675, 52 Stat. 1040 (1938) (codified as 
amended at 21 U.S.C. §§	301–399(f) (2012)).  
 75. Public Health Service Act, ch. 373, 58 Stat. 682 (1944) (codified as amended at 42 
U.S.C. §§	201–300mm-61 (2012)); see also Statement of Policy for Regulating 
Biotechnology Products, 49 Fed. Reg. 50,878, 50,878 (Dec. 31, 1984) (“The administrative 
review of products using biotechnology is based on the intended use of each product on a 
case-by-case basis.”). The proposed FDA regulation providing for the public disclosure of 
Investigational New Drug (“IND”) safety reports for gene-therapy studies “marked the 
first time that the FDA proposed to adopt formal regulations specifically dealing with 
gene therapy” as separate from biotechnology more generally. ANDREWS ET AL., supra 
note 58, at 406. 
 76. Important for our purposes, FDA oversight covers public and private institutions. 
As Grant noted in her piece: 
This is especially important with respect to CRISPR-Cas technology, which is easy 
to use, widely available, and inexpensive. Private institutions such as fertility 
clinics, are capable of using it without reliance on federal funding. Hence, federal 
legislation may be ineffective if it prohibits only funding of specific research 
activities. FDA authority over private institutions allow[s] it to regulate the private 
sector in situations in which federal legislative prohibitions do not explicitly 
address. 
See Grant, supra note 66, at 632. 
 77. See generally CTR. FOR BIOLOGICS EVALUATION & RESEARCH, FDA, 
GUIDANCE FOR INDUSTRY: GUIDANCE FOR HUMAN SOMATIC CELL THERAPY AND 
GENE THERAPY (1998), https://www.fda.gov/downloads/BiologicsBloodVaccines/
GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/
ucm081670.pdf [https://perma.cc/M4W3-9VGH] (intending to “provide manufacturers 
with current information regarding regulatory concerns for production, quality control 
testing, and administration of recombinant vectors for gene therapy; and of preclinical 
testing of both cellular therapies and vectors”). The guidance defines a gene therapy as “a 
medical intervention based on modification of the genetic material of living cells. Cells 
may be modified ex vivo for subsequent administration to humans, or may be altered in 
vivo by gene therapy given directly to the subject.” Id. at 3. 
 78. Id. at 4 (“IND applications for somatic cell and gene therapies should follow the 
same format and contain the same sections as IND’s for any investigational biological 
product, as described in 21 CFR 312.23.”). 
 79. See id. at 23. 
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(“IND”) application to the FDA.80 An IND application includes 
information about the results of initial testing, the compound’s 
composition and manufacturing, and a plan for how the sponsor 
intends to test the effects of the CRISPR compound on humans.81  
As described above, the guide RNA is one of the two main 
components of an engineered CRISPR system.82 The guide RNA 
component of the CRISPR system directs the system to its genomic 
target. Because a particular guide RNA is needed for a CRISPR 
system to reach a particular target, each system is theoretically useful 
for a very limited purpose. As such, FDA approval is sought—not for 
a generic CRISPR treatment applicable to all CRISPR systems, 
regardless of which guide RNA they contain, but rather for a discrete 
and specific CRISPR system.83 
After the FDA determines that the proposed study will not place 
human subjects under unreasonable risk of harm, the CRISPR system 
must go through three stages of clinical trials.84 First, the CRISPR 
 
 80. See The Drug Development Process, Step 3: Clinical Research, FDA (Jan. 4, 2018), 
https://www.fda.gov/ForPatients/Approvals/Drugs/ucm405622.htm [https://perma.cc/36XJ-
TKLC]. 
 81. See id. 
 82. See supra notes 33–34 and accompanying text.  
 83. See The Drug Development Process, Step 3: Clinical Research, supra note 80. The 
fact that CRISPR systems composed of different guide RNAs have to be approved by the 
FDA independently has important consequences for potential off-label uses. Historically, 
the FDA has lacked the authority to regulate the practice of medicine. See, e.g., Chaney v. 
Heckler, 718 F.2d 1174, 1179 (D.C. Cir. 1983) (noting that the legislative history of the 
Federal Food, Drug, and Cosmetic Act reflects congressional intent to prohibit the FDA 
from regulating the practice of medicine), rev’d on other grounds, 470 U.S. 821 (1985); 
David A. Kessler, The Regulation of Investigational Drugs, 320 NEW ENG. J. MED. 281, 
285 (1989). The agency itself accepted this view. See Legal Status of Approved Labeling 
for Prescription Drugs; Prescribing for Uses Unapproved by the Food and Drug 
Administration, 37 Fed. Reg. 16,503, 16,504 (Aug. 15, 1972) (“[I]t is clear that Congress 
did not intend the [FDA] to regulate or interfere with the practice of medicine .	.	.	.”). It’s 
the agency’s lack of authority over the practice of medicine that allows physicians to 
prescribe drugs for uses that the agency has not approved without violating federal law. 
See Kessler, supra, at 285. For example, the FDA approved ketamine for the treatment of 
pain in the early 1970s. See Gigen Mammoser, Ketamine Is Creating a New Wave of Drugs 
to Treat Depression, HEALTHLINE (June 13, 2018), https://www.healthline.com/health-
news/ketamine-creating-wave-of-drugs-to-treat-depression#1 [https://perma.cc/JQ5S-
AM7Z]. But it wasn’t until the year 2000 that ketamine’s efficacy as an antidepressant was 
discovered. Id. Once early reports of ketamine’s efficacy in treating depression surfaced, 
doctors began prescribing ketamine infusions to patients off-label. Id. This was before the 
FDA approved the drug for use as an antidepressant and, consequently, before clinical 
trials were able to uncover important safety and efficacy data. Id. Given that a CRISPR 
system containing a particular guide RNA is designed for a very specific target, off-label 
uses would be severely limited. 
 84. See What Are the Types of Clinical Research? (Jan. 4, 2018), FDA, 
https://www.fda.gov/ForPatients/ClinicalTrials/Types/default.htm [https://perma.cc/V8PY-
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system must undergo Phase I trials. Phase I trials are conducted on 
healthy human volunteers.85 During Phase II trials, investigators 
collect data on whether the CRISPR system actually works as 
intended.86 Those enrolled in Phase II trials have been diagnosed with 
the condition the CRISPR system intends to treat.87 Finally, large-
scale Phase III studies are conducted. During these trials, between 
300 and 3000 subjects diagnosed with the target condition are 
enrolled to gather more robust data on safety and effectiveness.88 
Only after all of those hurdles are successfully cleared will a CRISPR 
system obtain FDA approval for use in a clinical setting. 
Previous attempts at developing clinical applications for gene-
editing technologies drew critiques of the schemes implemented to 
regulate the drug approval process.89 Commentators, reflecting on the 
early rounds of clinical trials researching gene-editing therapies, 
noted that the monitoring of clinical trials needs improvement—
namely, more public disclosure and close collaboration between 
public regulatory agencies and specialized advisory boards.90 These 
and other concerns remain valid in the face of upcoming CRISPR 
clinical trials.91 
 
E48A] (noting that there are four phases of FDA trials but explaining that phase IV trials 
are “[p]ost-marketing studies, which are conducted after a treatment is approved for use 
by the FDA” (emphasis added)). 
 85. See The Drug Development Process, Step 3: Clinical Research, supra note 80. The 
number of people enrolled in phase I trials varies but usually falls between twenty and one 
hundred subjects. Id. The goal of this phase is to understand the most frequent side effects 
and the system’s kinetics. Id. 
 86. Id. Phase II trials are placebo controlled, meaning some people who enter the trial 
receive treatment with the CRISPR system while others do not. Safety and short-term side 
effects are also evaluated. See, e.g., A Phase 2, Randomized, Placebo-Controlled, 
Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for 




 87. The Drug Development Process, Step 3: Clinical Research, supra note 80. 
 88. Id.; see also Eva Andermann et al., Psychiatric and Cognitive Adverse Events: A 
Pooled Analysis of Three Phase III Trials of Adjunctive Eslicarbazepine Acetate for 
Partial-Onset Seizures, 82 EPILEPSY & BEHAV. 119, 121 (2018) (illustrating that the 
number of patients enrolled into phase III trials is often in the hundreds). 
 89. See Friedmann, supra note 57, at 2165. 
 90. Id.; see also Grant, supra note 66, at 617 (“[The] FDA was slow to answer the call 
for regulation of .	.	. gene therapy.”). 
 91. Recently, the FDA paused a CRISPR clinical trial slated to start in the United 
States and asked for more information to be included on the sponsor’s IND application. 
See Rich Haridy, FDA Hits Pause on One of the First US Human Clinical Trials to Use 
CRISPR, NEW ATLAS (May 31, 2018), https://newatlas.com/us-crispr-human-trial-hold-
fda/54862/ [https://perma.cc/8N4W-S3E9]. 
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II.  THE STATUS OF CRISPR FOR TREATING OR PREVENTING 
PSYCHIATRIC CONDITIONS 
Concededly, none of the clinical trials applying CRISPR 
technologies slated to start in either the United States or abroad 
involve applications to psychiatric disorders. While advances in 
neuroscience over the past few decades have been tremendous, the 
field itself is still rather young. And clinical translations of 
neuroscience research into psychiatry have proven challenging.92 
CRISPR, however, offers unique insights into the underlying biology 
of psychiatric disorders and may have an important and imminent 
role to play in developing therapies for a particular subset of 
psychiatric conditions. 
A. Review of Current Research in CRISPR Clinical Applications 
As of today, CRISPR systems have been successfully used to 
induce genetic modifications in a number of different species, 
including rats,93 mice,94 pigs,95 nonhuman primates,96 and human cell 
lines.97 But beyond CRISPR’s successful modification of genes, 
experiments have recently confirmed that CRISPR technology can 
actually be used in the treatment of inherited diseases. CRISPR-
induced modifications now have a targeted purpose and are used to 
achieve desired results. For example, CRISPR has successfully 
reintroduced normally functioning genes into the genome of a live 
animal, leading to the improvement of muscle function.98 Similarly, 
CRISPR has been used to enhance liver function and induce changes 
 
 92. See John Horgan, The Brain: The Final Frontier of Science, GLOBE & MAIL (Mar. 
29, 2018), https://www.theglobeandmail.com/technology/science/the-brain-the-final-frontier-
of-science/article1038205/ [https://perma.cc/72DG-TEND]. 
 93. See Benjamin Bakondi et al., In Vivo CRISPR/Cas9 Gene Editing Corrects Retinal 
Dystrophy in the S334ter-3 Rat Model of Autosomal Dominant Retinitis Pigmentosa, 24 
MOLECULAR THERAPY 556, 556 (2016). 
 94. See Simona Valletta et al., ASXL1 Mutation Correction by CRISPR/Cas9 Restores 
Gene Function in Leukemia Cells and Increases Survival in Mouse Xenografts, 6 
ONCOTARGET 44,061, 44,062 (2015). 
 95. See Luhan Yang et al., Genome-Wide Inactivation of Porcine Endogenous 
Retroviruses (PERVs), 350 SCIENCE 1101, 1101 (2015). 
 96. See Zhuchi Tu et al., Promoting Cas9 Degradation Reduces Mosaic Mutations in 
Non-Human Primate Embryos, 7 SCI. REP., no. 42081, Feb. 3, 2017, at 1, 1.  
 97. See generally Zhao Zhang et al., CRISPR/Cas9 Genome-Editing System in Human 
Stem Cells: Current Status and Future Prospects, 9 MOLECULAR THERAPY: NUCLEIC 
ACIDS 230, 230 (2017) (highlighting “the basic biology and application of the 
CRISPR/Cas9 system in current human stem cell research”).  
 98. Rodolphe Barrangou & Jennifer A. Doudna, Applications of CRISPR 
Technologies in Research and Beyond, 34 NATURE BIOTECHNOLOGY 933, 937 (2016). 
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in cholesterol metabolism in mice.99 Further, CRISPR has also 
successfully corrected genetic mutations and achieved functional 
restoration of simple genetic conditions in animal models.100 
In humans, a recently proposed clinical trial is looking to test the 
efficacy of a CRISPR system in cancer patients.101 The researchers 
will edit the immune cells of the participants.102 Scientists in China 
have successfully edited genes in human embryos, replacing a 
thalassemia-causing gene with its corrected form and achieving 
desired results.103 U.S.-based companies have launched clinical trials 
for the application of CRISPR technologies to treat the ββ-
thalassemia blood disorder.104 Together, these applications suggest 
that CRISPR might be used successfully to correct human diseases 
arising from single-gene mutations, where the target is clear and the 
causal underpinnings of the disease are well understood. 
Particularly in the context of psychiatry and neuropsychiatric 
diseases, CRISPR systems have been used to study the roles of 
different proteins in directing neurodevelopment so as to better 
understand the function of pathways that regulate genes and their 
expression.105 Studies using CRISPR on genes implicated in Autism 
Spectrum Disorder (“ASD”) have successfully induced changes in the 
size and morphology of mouse neurons.106 And a study using CRISPR 
 
 99. Id.  
 100. See generally Nataša Savić & Gerald Schwank, Advances in Therapeutic 
CRISPR/Cas-9 Genome Editing, 168 TRANSLATIONAL RES. 15 (2016) (collecting 
examples of successful CRISPR applications in restoring function). 
 101. See Françoise Baylis & Marcus McLeod, First-in-Human Phase 1 CRISPR Gene 
Editing Cancer Trials: Are We Ready?, 17 CURRENT GENE THERAPY 309, 309 (2017). 
 102. See id. at 310. 
 103. See Ewen Callaway, Embryo-Editing Research Gathers Momentum, 532 NATURE 
289, 290 (2016) (discussing Puping Liang et al., CRISPR/Cas9-Mediated Gene Editing in 
Human Tripronuclear Zygotes, 6 PROTEIN & CELL 363, 363 (2015)). Thalassemia is “an 
inherited blood disorder characterized by the presence of less hemoglobin and fewer red 
blood cells in your body than normal.” Thalassemia, MAYO CLINIC (Nov. 2, 2016), 
https://www.mayoclinic.org/diseases-conditions/thalassemia/symptoms-causes/syc-20354995 
[https://perma.cc/39ZX-X7ZK]. 
 104. A Safety and Efficacy Study Evaluating CTX001 in Subjects with Transfusion-
Dependent ββ-Thalassemia, CLINICALTRIALS.GOV, https://clinicaltrials.gov/ct2/show/
NCT03655678 [https://perma.cc/S9DJ-9GJX] (last updated Feb. 4, 2019).  
 105. See, e.g., Elizabeth A. Alcamo et al., Satb2 Regulates Callosal Projection Neuron 
Identity in the Developing Cerebral Cortex, 57 NEURON 364, 364 (2008). 
 106. See, e.g., Eric Deneault et al., Complete Disruption of Autism-Susceptibility Genes 
by Gene Editing Predominantly Reduces Functional Connectivity of Isogenic Human 
Neurons, 11 STEM CELL REP. 1211, 1211 (2018) (“[P]resent[ing] a CRISPR gene editing 
strategy to insert a protein tag and premature termination sites creating an induced 
pluripotent stem cell (iPSC) knockout resource for functional studies of ten ASD-relevant 
genes .	.	.	.”); Michael R. Williams et al., A Retroviral CRISPR-Cas9 System for Cellular 
Autism-Associated Phenotype Discovery in Developing Neurons, 6 SCI. REP., no. 25611, 
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to knock out genetic variants repeatedly associated with 
schizophrenia has helped scientists understand the impact of disease-
relevant mutations.107 Fragile X syndrome—thought to be the most 
common form of inherited intellectual disability—is caused by a 
known repeat in a specific gene.108 This repeat causes certain changes 
to the genome.109 Using CRISPR, scientists have deleted the 
nucleotide repeat known to cause Fragile X.110 The deletion reversed 
some of the known harmful downstream consequences of the repeat 
sequence.111 
B. CRISPR in Psychiatry: More Immediate Practical Applications 
The state of the science reveals areas where CRISPR might find 
more immediate practical application. As noted above, preclinical 
findings of studies involving CRISPR systems suggest that the 
technology might be successfully used to correct human diseases 
arising from single-gene mutations, known as monogenic diseases.112 
There are certain conditions with psychiatric manifestations that are 
known to have monogenic causes and genetically defined symptoms. 
The Diagnostic and Statistical Manual of Mental Disorders 
(“DSM-5”)—the definitive manual used by psychiatrists and other 
mental health experts for the diagnosis and treatment of psychiatric 
disorders—devotes an entire section to neurocognitive disorders 
(“NCDs”).113 Most NCDs have an adult onset.114 For many, there is a 
 
May 10, 2016, at 1, 1 (concluding that the implementation of a CRISPR system is an 
efficient system for an Autism-associated phenotype discovery in wild-type animals). 
 107. See Matthew D. Rannals et al., Psychiatric Risk Gene Transcription Factor 4 
Regulates Intrinsic Excitability of Prefrontal Neurons via Repression of SCN10a and 
KCNQ1, 90 NEURON 43, 43, 45 (2016). 
 108. X. Shawn Liu et al., Rescue of Fragile X Syndrome Neurons by DNA Methylation 
Editing of the FMR1 Gene, 172 CELL 979, 979 (2018). 
 109. See id. One of the changes that occurs is DNA methylation. Methylation is the 
process by which genes are turned “on” and “off.” See Cath Ennis, Epigenetics 101: A 
Beginner’s Guide to Explaining Everything, GUARDIAN (Apr. 25, 2014), 
https://www.theguardian.com/science/occams-corner/2014/apr/25/epigenetics-beginners-guide-
to-everything [https://perma.cc/RF4F-ZVGG]. When genes are on, they produce proteins. 
Id. 
 110. See Chul-Yong Park et al., Reversion of FMR1 Methylation and Silencing by 
Editing the Triplet Repeats in Fragile X iPSC-Derived Neurons, 13 CELL REP. 234, 234 
(2016). 
 111. See id. 
 112. See supra notes 93–104 and accompanying text.  
 113. See AM. PSYCHIATRIC ASS’N, DIAGNOSTIC AND STATISTICAL MANUAL OF 
MENTAL DISORDERS 591–644 (5th ed. 2013) [hereinafter DSM-5]. “The NCDs are unique 
among DSM-5 categories in that these are syndromes for which the underlying pathology, 
and frequently the etiology as well, can potentially be determined. The various underlying 
97 N.C. L. REV. 1359 (2019) 
2019] CRISPR IN PSYCHIATRY 1377 
variation of the disorder that is inherited and for which a causative 
genetic mutation has been identified.115 
One such example is noted above. Fragile X presents in humans 
when a single gene, known as the FMR1 gene, shuts down. When a 
gene shuts down, it stops producing proteins.116 In one study, scientists 
successfully applied CRISPR systems to remove the tags on the 
FMR1 gene that are responsible for keeping the gene shut off.117 As a 
result, the genes began producing proteins normally again, and once 
the edited cells were transferred into mice, the cells continued to 
produce proteins normally for a subsequent three months.118 These 
results were astounding: the test achieved almost full restoration of 
normal protein expression levels of the FMR1 gene.119 This means 
that scientists may, in the not-so-distant future, be able to engineer a 
lasting solution for Fragile X syndrome.  
Similar to Fragile X, Huntington’s disease is also caused by a 
single, identifiable genetic mutation.120 In cells from both animal 
models and humans, CRISPR was able to deactivate Huntington’s 
defective gene with remarkable efficiency.121 Clinical testing on 
Huntington’s could be expected to start as early as five years from 
now.122 
 
disease entities have all been the subject of extensive research, clinical experience, and 
expert consensus on diagnostic criteria.” Id. at 591. 
 114. Major Neurocognitive Disorder in Adults, MINDYRA, http://www.mindyra.com/
solutions/adults/majorneurocognitivedisorder [https://perma.cc/LXH5-GVCG]. 
 115. Some of the disorders that fall within this category are as follows: NCD due to 
Alzheimer’s disease, NCD due to Parkinson’s disease, NCD with Lewy Bodies, 
Frontotemporal NCD, and NCD due to Huntington’s disease. DSM-5, supra note 113, at 
591. For Huntington’s disease in particular, the diagnosis is made by genetic confirmation 
of the causative genetic mutation. Huntington Disease, NIH: NAT’L CTR. FOR 
ADVANCING TRANSLATIONAL SCI. (July 8, 2015), https://rarediseases.info.nih.gov/
diseases/6677/huntington-disease/cases/18858 [https://perma.cc/E9RF-GLLF].  
 116. See Fragile X Syndrome, NIH: GENETICS HOME REFERENCE, 
https://ghr.nlm.nih.gov/condition/fragile-x-syndrome#genes [https://perma.cc/5L8R-APG5] (last 
updated Apr. 30, 2019).  
 117. See Liu et al., supra note 108, at 979.  
 118. Id. at 984–85. 
 119. See id. at 979. 
 120. Alex Mas Monteys et al., CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In 
Vitro and In Vivo, 25 MOLECULAR THERAPY 12, 12 (2017). 
 121. See id. at 19–20. Increasing scientific evidence supports eliminating the distinction 
between psychiatric and neurological disorders. See P. D. White, H. Rickards & A. Z. J. 
Zeman, Time to End the Distinction Between Mental and Neurological Illnesses, 344 BRIT. 
MED. J., no. e3454, May 24, 2012, at 1,1.  
 122. Michael Eisenstein, CRISPR Takes on Huntington’s Disease, NATURE (May 30, 
2018), https://www.nature.com/articles/d41586-018-05177-y#ref-CR1 [https://perma.cc/4T47-
YVVW]. 
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CRISPR might also be more immediately applied to 
mitochondrial disorders with psychiatric phenotypes, such as 
Niemann-Pick disease. Niemann-Pick is a rare and life-threatening 
condition—frequently diagnosed in children during their elementary 
school years—in which cholesterol and other lipids are not properly 
metabolized within the cell.123 The disease is sometimes referred to as 
“childhood Alzheimer’s”124 and has a known genetic cause.125 There 
are currently no viable treatments or cures for Niemann-Pick,126 but 
the disorder has been identified as one that might be among the first 
treated with CRISPR technologies.127 
Wilson’s disease is another particularly interesting target. This 
genetic disorder often presents with neuropsychiatric symptoms, but 
it primarily involves the liver.128 Given that psychiatric symptoms can 
be these patients’ chief complaint, a true diagnosis often eludes 
clinicians for some time.129 It’s the mutation of a single gene, ATP7B, 
that leads to Wilson’s disease.130 And the possibility of delivering gene 
therapy to the liver is much more tractable at this time than 
interventions targeting the brain directly.131 
 
 123. Niemann Pick Disease Type C, NAT’L ORG. FOR RARE DISORDERS, 
https://rarediseases.org/rare-diseases/niemann-pick-disease-type-c/ [http://perma.cc/B8W7-
CW36].  
 124. Univ. of Pa., Effective Treatment for Niemann Pick Type C Identified, 
SCIENCEDAILY (Feb. 25, 2015), https://www.sciencedaily.com/releases/2015/02/150225151752.
htm [http://perma.cc/T37F-U4MA].  
 125. Mary Gearing, Treating Muscular Dystrophy with CRISPR Gene Editing, 
ADDGENE BLOG (Jan. 26, 2016, 10:30 AM), https://blog.addgene.org/treating-muscular-
dystrophy-with-crispr-gene-editing [http://perma.cc/688P-NB5U]. 
 126. See Erica Peacock, Gene Therapy: Bringing Hope to the Rare Disease Community, 
RARE DISEASE REV. (Mar. 12, 2018), https://www.rarediseasereview.org/publications/2018/
3/12/gene-therapy-bringing-hope-to-the-rare-disease-community [http://perma.cc/7QDM-
SZNK]. 
 127. See Gearing, supra note 125. 
 128. Wilson Disease, NIH: NAT’L INST. DIABETES & DIGESTIVE & KIDNEY DISEASES, 
https://www.niddk.nih.gov/health-information/liver-disease/wilson-disease [http://perma.cc/
48QS-FZ3Z].  
 129. GEORGE J. BREWER, WILSON’S DISEASE: A CLINICIAN’S GUIDE TO 
RECOGNITION, DIAGNOSIS, AND MANAGEMENT 4 (2001). 
 130. Id. at 139. 
 131. As noted above, it is important to keep in mind that, although a single gene may 
be involved in the etiology of these conditions, there may be multiple causative mutations 
within that single gene. 
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C. Likelihood of CRISPR Applications to Polygenic Psychiatric 
Disorders 
With technology as it currently stands, targeting psychiatric 
disorders caused by multiple genes—polygenic conditions132—is a 
distant reality. To be sure, recent preclinical studies have managed to 
enhance CRISPR’s target specificity and use certain CRISPR systems 
containing multiple guide RNAs to target many genes at once—a task 
known as multiplexing.133 But because of the complicated and largely 
unknown genetic architecture of polygenic psychiatric disorders, 
along with the effects of complex epigenetic processes for which we 
still can’t account, CRISPR clinical applications in this area aren’t 
likely an imminent reality. Even if CRISPR were shown to be 
efficacious in a clinical setting, the editing targets for most psychiatric 
disorders—certainly all polygenic psychiatric disorders—are not yet 
clear. 
One reason for this complexity is the lack of understanding about 
the role of noncoding, gene-regulatory regions in neuropsychiatric 
disease. The coding region of a gene contains the instructions for the 
production of proteins. Coding regions make up about one percent of 
all DNA.134 Noncoding regions make up the other ninety-nine percent 
and, until very recently, were referred to as “junk DNA.” Noncoding 
regions were thought to have no purpose at all.135 Consequently, 
much of the research in genetics has been focused on DNA’s coding 
regions.136 As it turns out, however, this focus may have been 
misguided, as noncoding regions play a more important role in 
polygenic disorders than was previously believed. For instance, one 
article identified 108 loci associated with schizophrenia, and a great 
many happened to occur in noncoding regions.137 Accordingly, though 
 
 132. What Are Complex or Multifactorial Disorders?, NIH: GENETICS HOME 
REFERENCE, https://ghr.nlm.nih.gov/primer/mutationsanddisorders/complexdisorders 
[https://perma.cc/5SBD-BDSA] (last updated Apr. 30, 2019).  
 133. Mary Gearing, CRISPR 101: Multiplex Expression of gRNAs, ADDGENE BLOG 
(Jan. 28, 2016, 10:50 AM), https://blog.addgene.org/crispr-101-multiplex-expression-of-grnas 
[http://perma.cc/5CWM-MD5N]. 
 134. Jonathan Henninger, The 99 Percent .	.	. of the Human Genome, HARV. U.: SCI. 
NEWS (Oct. 1, 2012), http://sitn.hms.harvard.edu/flash/2012/issue127a/ [http://perma.cc/
7VQ3-RXR7].  
 135. Stephen S. Hall, Hidden Treasures in Junk DNA, SCI. AM. (Oct. 1, 2012), 
https://www.scientificamerican.com/article/hidden-treasures-in-junk-dna/ [http://perma.cc/
3WUN-8E6S]. 
 136. Id. 
 137. Schizophrenia Working Grp. of the Psychiatric Genomics Consortium, Biological 
Insights from 108 Schizophrenia-Associated Loci, 511 NATURE 421, 421–22 (2014) (“Of 
the 108 loci, 75% include protein-coding genes .	.	.	.”).  
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noncoding regions are now garnering more attention, further 
investigation is still needed to fully understand their role in 
neuropsychiatric diseases. 
Among polygenic psychiatric disorders, the genetics of 
schizophrenia are best understood. This is, in part, due to the fact that 
the heritability of schizophrenia has been estimated to be as high as 
eighty-seven percent.138 After decades of research, it has been 
determined that genes play a very important role in the development 
of schizophrenia. Scientists have successfully located multiple 
alterations in the genomic DNA of neurons and discovered that they 
are, in fact, likely responsible for causing the disorder.139 Yet obstacles 
such as CRISPR’s inability to cross the blood-brain barrier, lack of 
definite targets, genetic overlap between schizophrenia and other 
psychiatric conditions, and lack of knowledge about the efficacy and 
long-term safety of CRISPR systems mean there is a long way to go 
before CRISPR technologies can be translated into a clinical cure for 
schizophrenia.140 
Another obstacle to applying CRISPR for the treatment of 
psychiatric disorders concerns neurodevelopmental disorders. Take, 
for example, intellectual developmental disorder (“IDD”) and ASD. 
Sequencing efforts of IDD cases have been successful. Studies have 
now identified a genetic cause for up to forty percent of severe IDD 
cases.141 But for many of the genetically defined IDD cases, most of 
the deleterious effects of the identified pathogenic genomic variants 
may have already taken place by the time of diagnosis.142 This is the 
case even though the diagnosis can take place as early as in utero.143 It 
is not apparent that changing a pathogenic variant after birth would 
correct the associated behaviors and phenotype. 
Nonetheless, it is possible that repair by CRISPR may improve 
some aspects of psychiatric symptomatology. After all, current 
 
 138. See Alastair G. Cardno et al., Heritability Estimates for Psychotic Disorders: The 
Maudsley Twin Psychosis Series, 56 ARCHIVES GEN. PSYCHIATRY 162, 162 (1999). This 
means the closer the familial relationship, the higher the risk for developing schizophrenia. 
 139. Stephan Ripke et al., Genome-Wide Association Analysis Identifies 13 New Risk 
Loci for Schizophrenia, 45 NATURE GENETICS 1150, 1150 (2013). 
 140. Chuanjun Zhuo et al., Genomic Editing of Non-Coding RNA Genes with 
CRISPR/Cas9 Ushers in a Potential Novel Approach to Study and Treat Schizophrenia, 10 
FRONTIERS MOLECULAR NEUROSCIENCE, no. 28, Feb. 3, 2017, at 1, 6–7.  
 141. Simone M. Karam et al., Genetic Causes of Intellectual Disability in a Birth 
Cohort: A Population-Based Study, 167A AM. J. MED. GENETICS 1204, 1211 (2015). 
 142. Id. at 1207. 
 143. See Regie Lyn P. Santos-Cortez et al., Novel Candidate Genes and Variants 
Underlying Autosomal Recessive Neurodevelopmental Disorders with Intellectual 
Disability, 137 HUM. GENETICS 735, 744 (2018). 
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psychopharmacologic treatments available today, which target 
behaviors, do not directly address underlying structural 
abnormalities.144 
A final important consideration is the fact that many of the 
identified causative variants are exceedingly rare. That is, though a 
particular gene may have clear associations with IDD, there are often 
numerous variants within that gene that led to each particular 
individual’s case of IDD.145 Targeting and identifying each and every 
one of those possible pathogenic variants within the single gene 
presents another daunting challenge. 
Certainly, CRISPR techniques hold much promise as important 
tools in helping us understand the biology underlying 
neuropsychiatric disorders. CRISPR is illuminating pathways beyond 
the reach of older technologies.146 Its translation into the clinical 
setting, however, would necessarily depend upon its ability to reveal 
the biological mechanisms responsible for psychiatric conditions. 
For the time being, therefore, the brain remains a daunting 
target. Given its cellular and structural complexity, relative 
inaccessibility, irreplaceable function, and minimal regenerative 
capacity, neuropsychiatric conditions will not likely serve as 
CRISPR’s initial testing grounds. But CRISPR technology is 
developing quickly, and clinical applications in the future—for certain 
disorders—are no longer improbable hypotheticals.147 Before these 
become a reality, scientists and clinicians need a better understanding 
of the technology and its unintended effects.148 Likewise, many have 
called for discourse on the ethical issues implicated by CRISPR 
applications.149 
 
 144. Laura Weiss Roberts & Shaili Jain, Ethical Issues in Psychopharmacology, 
PSYCHIATRIC TIMES (May 7, 2011), http://www.psychiatrictimes.com/geriatric-psychiatry/
ethical-issues-psychopharmacology [http://perma.cc/S9MD-7CTT]. 
 145. See generally Jay W. Ellison, Jill A. Rosenfeld & Lisa G. Shaffer, Genetic Basis of 
Intellectual Disability, 64 ANN. REV. MED. 441 (2013) (discussing how the proliferation of 
microarray analysis has led scientists to the conclusion that there is “extensive genetic 
heterogeneity” for intellectual disability). 
 146. For example, scientists are developing reliable animal models and investigating 
the role of long noncoding RNA functions and higher-order chromatin structures. 
Prashanth Rajarajan et al., Spatial Genome Organization and Cognition, 17 NATURE 
REVIEWS: NEUROSCIENCE 681, 688 (2016). 
 147. See id. at 685.  
 148. See, e.g., Zhuo et al., supra note 140, at 6–7. 
 149. Id. 
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III.  LEGAL AND ETHICAL CHALLENGES OF CRISPR IN THE 
CONTEXT OF PSYCHIATRIC ILLNESS 
The use of CRISPR technologies in psychiatric populations must 
conscientiously regard the dubious past of American law on the 
intersection of psychiatric disorders and genetics. The legal and 
ethical issues that arise as CRISPR technologies become available 
have, to some extent, all been seen before. After all, the goal of gene 
therapy could be characterized as removing genetic defects from the 
population. And what is the genetic cleansing of a human population 
if not the issue addressed by the incendiary Supreme Court decision 
in Buck v. Bell?150 Careful thought will be particularly important 
within the delicate context of psychiatry given this subgroup’s.151 
A. Vulnerability of Patients Likely to Enlist in CRISPR Research in 
Psychiatry 
Attempts to define vulnerability within the medical community 
have been criticized by some for being wildly inconsistent and for 
producing definitions that are entirely too broad.152 As we have noted 
above, the medical community typically includes those diagnosed with 
mental illness within the vulnerable population label.153 For research 
purposes, however, patients diagnosed with psychiatric disorders 
historically have not been labeled as vulnerable, and those enrolled in 
clinical trials for psychiatric disorders are therefore not always 
 
 150. 274 U.S. 200 (1927). In this case, the United States Supreme Court reviewed the 
constitutionality of Virginia’s Sterilization Act, under the authority of which the State 
proposed to have Carrie Buck sterilized. Id. at 205–06. Officials of the Virginia Colony 
asserted that Carrie and her mother shared the hereditary traits of feeblemindedness and 
sexual promiscuity. Id. The Court voted 8-1 to allow Buck’s sterilization and, by extension, 
the sterilization of any other American in similar circumstances. See id. at 207. Justice 
Holmes, writing for the majority, concluded with the unfortunate remark: “Three 
generations of imbeciles are enough.” Id.  
 151. In the domain of health care, vulnerable populations include those with chronic 
mental conditions such as schizophrenia, bipolar disorder, and major depression. As we 
will address later, this designation does not extend into the domain of clinical research. See 
Samia A. Hurst, Vulnerability in Research and Health Care; Describing the Elephant in the 
Room?, 22 BIOETHICS 191, 192 (2008). The vulnerable-population label denotes a 
reference to a disadvantaged subsegment of people. Id. at 191–92. The term for our 
purposes implies that these subgroups require utmost care, given that their freedom and 
capability to protect themselves from intended or inherent risks is abbreviated, be it from 
an impairment of freewill or an inability to make informed choices. See id. 
 152. See Philip T. Yanos, Barbara S. Stanley & Carolyn S. Greene, Research Risk for 
Persons with Psychiatric Disorders: A Decisional Framework to Meet the Ethical 
Challenge, 60 PSYCHIATRIC SERVICES 374, 375 (2009). 
 153. See supra note 151.  
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afforded additional safeguards.154 In the sections that follow, we’ll 
consider whether subjects enrolled in CRISPR clinical trials should be 
labeled as a vulnerable population for research purposes. In so doing, 
we describe the likely characteristics shared by these patients and 
turn to both examples of capacity155 and power-based vulnerabilities156 
affecting these subjects. 
1.  The Population Most Likely to Undergo CRISPR Clinical Trials Is 
Treatment Resistant 
Despite the vast amounts of resources invested into the 
exploration of their genetic architecture, there are still no biomarkers 
that allow for conclusive diagnoses of major psychiatric disorders.157 
In a sense, much of clinical practice in psychiatry still relies on self-
reports, observations, and trial-and-error treatment selection.158 That 
is, biologically heterogeneous conditions in psychiatry are often 
treated generally, since treatments that are most likely to help a 
particular individual cannot be identified.159 
To be sure—and as Section II.A illustrates—the explosion of 
research in genetics, particularly in the field of psychiatry, has 
produced some fruitful information.160 Psychiatric disorders’ high 
rates of heritability have become more apparent than ever before.161 
Simultaneously, these studies reveal that, for most disorders, there is 
a complex genetic architecture that provides multiple potential 
targets for CRISPR interventions. Though most of the genes 
identified are only responsible in very small part for the overall risk of 
developing a disorder,162 as noted above, there are variants that seem 
 
 154. See, e.g., 45 C.F.R. §	46.107 (2018) (not including those diagnosed with psychiatric 
disorders in its list of vulnerable populations).  
 155. Capacity-based vulnerability is the vulnerability that arises as a consequence of 
subjects having an impaired capacity to provide fully informed consent. See Yanos et al., 
supra note 152, at 375. 
 156. Power-based vulnerability is vulnerability due to a population being generally 
more susceptible to social influence and the commands of authority figures. Id. 
 157. Daniel Moreno-De-Luca, Michael E. Ross & David A. Ross, Leveraging the 
Power of Genetics to Bring Precision Medicine to Psychiatry: Too Little of a Good Thing?, 
83 BIOLOGICAL PSYCHIATRY e45, e45 (2018). 
 158. See JAMES H. LAKE, TEXTBOOK OF INTEGRATIVE MENTAL HEALTH CARE 18 
(2007).  
 159. See Moreno-De-Luca et al., supra note 157, at e45.  
 160. See id.  
 161. See id.; see also Gandal et al., supra note 3, at 1397. Most notably, the genetic 
contribution to the condition of schizophrenia has been placed at seventy-nine percent. 
Rikke Hilker et al., Heritability of Schizophrenia and Schizophrenia Spectrum Based on 
the Nationwide Danish Twin Register, 83 BIOLOGICAL PSYCHIATRY 492, 495 (2018). 
 162. See Moreno-De-Luca et al., supra note 157, at e45. 
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more promising. That said, for a majority of conditions, there is still a 
great deal left to learn. 
Even if a psychiatric disorder presented with clear symptoms and 
had a clear genetic target the prospect of CRISPR intervention poses 
dilemmas. First, there are likely biological consequences to living with 
a pathogenic variant for years,163 and it’s likely that these 
consequences cannot be immediately accounted for by simply 
replacing the affected gene sequence with a new one. Second, we are 
only beginning to understand the genetic architecture of psychiatric 
disorders, as well as the epigenetic components of psychiatric 
symptomatology.164 Targeting genes that are believed to be 
responsible for disorders may not have the intended therapeutic 
effect because the intervention does not address the epigenetics 
involved in the etiology of the condition. 
Against this background, it becomes clear that treatments 
applying CRISPR systems should be thought of as highly 
experimental.165 And because it intends to change one of the most 
fundamental aspects of our biology, CRISPR should be understood as 
highly invasive. Clinical trials looking to apply invasive and 
experimental technologies to psychiatric populations provide ample 
precedent for a description of the groups usually recruited for 
enrollment. For example, Electroconvulsive Therapy (“ECT”) trials 
are usually conducted on patient populations that are considered 
treatment resistant: patients who have tried numerous interventions 
to no avail.166 ECT is considered highly invasive for a number of 
 
 163. A pathogenic variant can be thought of as a “faulty gene.”  
 164. See Rachel Yehuda et al., Holocaust Exposure Induced Intergenerational Effects 
on FKBP5 Methylation, 80 BIOLOGICAL PSYCHIATRY 372, 379 (2016). 
 165. See David Crow, CRISPR Gene Editing Ready for Testing in Humans, FIN. TIMES 
(Mar. 5, 2018), https://www.ft.com/content/d6a773a0-cece-11e7-947e-f1ea5435bcc7 
[http://perma.cc/2VUT-834X] (“The field is in its infancy and progress in any new area of 
science is never smooth.”).  
 166. See Nancy Kerner & Joan Prudic, Current Electroconvulsive Therapy Practice and 
Research in the Geriatric Population, 4 NEUROPSYCHIATRY 33, 34 (2014) (“[ECT] is 
utilized worldwide for various severe and treatment-resistant psychiatric disorders.”); Eric 
L. Ross, Kara Zivin & Daniel F. Maixner, Cost-Effectiveness of Electroconvulsive Therapy 
vs Pharmacotherapy/Psychotherapy for Treatment-Resistant Depression in the United 
States, 75 JAMA PSYCHIATRY 713, 714 (2018) (“Although ECT can be a first-line 
treatment for depression with life-threatening psychotic or suicidal features, it is most 
often used in the United States for depression that has failed to respond to 
pharmacotherapy and/or psychotherapy.”); What Is Electroconvulsive Therapy (ECT)?, 
AM. PSYCHIATRIC ASS’N, https://www.psychiatry.org/patients-families/ect 
[http://perma.cc/FF7H-6S85] (“Electroconvulsive therapy (ECT) is a medical treatment 
most commonly used in patients with severe major depression or bipolar disorder that has 
not responded to other treatments.”). The definition of “treatment resistance” in 
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reasons, primarily the need for general anesthesia during the 
therapy’s administration.167 Similarly, experimental trials in psychiatry 
involving the use of ketamine, scopolamine, and other psychedelics 
target treatment-resistant patients.168 The same is true of trials 
involving invasive deep brain stimulation procedures.169 Invasive and 
innovative interventions are usually reserved for those patients who 
either have not responded to numerous treatments over a long period 
of time and have been continuously affected by the symptoms they 
deem undesirable170 or those who have been unable to tolerate the 
side effects of traditional psychotropic medications. 
Arguably, intervention with gene-editing technologies is more 
invasive than intervention with ECT, ketamine, and the other highly 
invasive treatments discussed above. Unlike currently available 
interventions, treatment with CRISPR for psychiatric disorders would 
likely entail direct exposure of biologics to the brain, lead to 
permanent change in the patient’s genetic blueprint, and require 
 
psychiatry varies and is usually defined in the context of the disorder diagnosed. For 
example, treatment-resistant depression “typically refers to the occurrence of an 
inadequate response following adequate antidepressant therapy among patients suffering 
from unipolar depressive disorders.” Maurizio Fava, Diagnosis and Definition of 
Treatment-Resistant Depression, 53 BIOLOGICAL PSYCHIATRY 649, 649 (2003). In the 
context of schizophrenia, treatment resistance—also known as treatment refractoriness—
has been “defined as continuing psychotic symptoms with substantial functional disability 
and/or behavioral deviances that persist in well-diagnosed persons with schizophrenia 
despite reasonable and customary pharmacological and psychosocial treatment that has 
been provided continuously for an adequate time period.” Hans D. Brenner et al., 
Defining Treatment Refractoriness in Schizophrenia, 16 SCHIZOPHRENIA BULL. 551, 552–
53 (1990); see also Norman Sussman, Introduction: Treatment Resistance in Psychiatry, 
PSYCHIATRIC TIMES (Nov. 27, 2017), https://www.psychiatrictimes.com/special-reports/
introduction-treatment-resistance-psychiatry [https://perma.cc/2DZB-2GHZ].  
 167. See What Is Electroconvulsive Therapy (ECT)?, supra note 166. 
 168. See, e.g., James W. Murrough et al., Antidepressant Efficacy of Ketamine in 
Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial, 170 AM. 
J. PSYCHIATRY 1134, 1135 (2013); Chun Yang & Kenji Hashimoto, Letter to the Editor, 
Combination of Nitrous Oxide with Isoflurane or Scopolamine for Treatment-Resistant 
Major Depression, 13 CLINICAL PSYCHOPHARMACOLOGY & NEUROSCIENCE 118, 118 
(2015); see also Carlos Zarate et al., New Paradigms for Treatment-Resistant Depression, 
1292 ANNALS N.Y. ACAD. SCI. 21, 25 (2013). 
 169. See Paul E. Holtzheimer & Helen S. Mayberg, Deep Brain Stimulation for 
Psychiatric Disorders, 34 ANN. REV. NEUROSCIENCE 289, 290 (2011). 
 170. Although a precise definition of treatment resistance is hard to come by and often 
varies depending on the particular psychiatric disorder at issue, some have characterized 
treatment resistance as “patients who experience persistent psychiatric symptoms with 
impaired functioning despite one or more adequate treatment trials.” L. Fredrik Jarskog, 
Book Review, 171 AM. J. PSYCHIATRY 374, 374 (2014) (reviewing CHARLES B. 
NEMEROFF, MANAGEMENT OF TREATMENT-RESISTANT MAJOR PSYCHIATRIC 
DISORDERS (2012)); see also supra note 166.  
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genetic sequencing prior to CRISPR’s application.171 Therefore, it is 
reasonable to assume that, if and when the technology is developed, 
the same population of treatment-resistant patients would make for 
the best candidates for CRISPR clinical trials in psychiatry. To be 
sure, if gene-editing technology trials of the past are any indication, 
those who enroll in these research studies will be treatment resistant 
and may be willing to consider riskier interventions to address their 
symptoms.172 
2.  Risk-Benefit Analysis for Testing CRISPR in Treatment-Resistant 
Populations 
The target of treatment for patients with psychiatric disorders is 
“to restore a state of psychological wellness and high functioning.”173 
In deciding how to reach this goal, physicians must conduct a risk-
benefit analysis for prescribing psychotropic medications or 
alternative therapies. As this analysis relates to any patient diagnosed 
with a psychiatric disorder, the balancing is particularly complex.174 
Lackluster therapeutic and diagnostic precision, psychosocial factors, 
common comorbidities, and the high importance given to the 
subjective experiences of patients complicate the prescribing 
physicians’ decisionmaking processes.175 For a favorable risk-benefit 
ratio to exist, biological, psychological, and social factors must align.176 
The already delicate balance changes when a patient diagnosed with a 
psychiatric disorder experiences treatment resistance. 
Treatment-resistant patients typically feel debilitated for a long 
period of time,177 experience feelings of hopelessness and 
 
 171. The privacy implications of gathering genetic-sequencing information from 
patients prior to treatment are discussed infra Section III.A.3. 
 172. See Friedmann, supra note 57, at 2163–65. In the alternative, as noted in Section 
II.B, trials will target monogenic diseases for which there is no cure. Just like treatment-
resistant patients, the patients affected by the monogenic disorders that have no viable 
treatment alternatives are most likely to be targeted by CRISPR in the near future. Both 
groups face parallel ethical dilemmas as a result. This discussion, therefore, will proceed 
by considering the implications of clinical research in a treatment-resistant population. 
 173. Maurizio Fava & Katharine G. Davidson, Definition and Epidemiology of 
Treatment-Resistant Depression, 19 PSYCHIATRIC CLINICS N. AM. 179, 179 (1996).  
 174. Swapnil Gupta & John Daniel Cahill, A Prescription for “Deprescribing” in 
Psychiatry, 67 PSYCHIATRIC SERVICES 904, 904 (2016). 
 175. Id. 
 176. Id. 
 177. See Jarskog, supra note 170, at 375 (“Most [psychiatric] disorders do not have 
formally defined treatment-resistant subtypes, but the prevalence of persistent and 
debilitating symptoms is a ubiquitous problem.”). 
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helplessness,178 and may be at risk of suicide.179 Therefore, treatment-
resistant patients—along with their treating physicians—are generally 
more willing to take risks to find a solution.180 Accordingly, 
institutional review boards and other regulatory bodies are more 
likely to allow invasive interventions if the population being treated is 
treatment-resistant and/or has few or no alternative options. After all, 
the risk of not acting might outweigh any risks that an invasive 
intervention like CRISPR might pose.181 Ultimately, however, 
clinicians and researchers should understand the characteristics and 
symptoms of treatment-resistant patients as having the effect of 
altering not only the risk-benefit analysis for available treatment 
options but also the power differential between patients, clinicians, 
and researchers. As a particularly affected subgroup of a population 
already stigmatized and underserved,182 treatment-resistant 
individuals should be considered at high risk for power-based 
vulnerability and coercion. 
3.  Treatment-Resistant Patients with Psychiatric Conditions Are 
Highly Stigmatized 
To some extent, the severity or presentation of treatment-
resistant conditions is intertwined183 with the stigma faced by all 
individuals diagnosed with psychiatric disorders.184 Issues of power-
based vulnerability also arise if one considers the consequences of 
stigma attached to mental health issues. A clinician or researcher who 
 
 178. See, e.g., Murrough et al., supra note 168, at 1134 (“The primary outcome was 
change in depression severity .	.	. as assessed by the Montgomery-Åsberg Depression 
Rating Scale.”); see also Stuart A. Montgomery & Marie Åsberg, A New Depression Scale 
Designed to be Sensitive to Change, 134 BRIT. J. PSYCHIATRY 382, 388 (1979) (measuring, 
among other things, whether subjects experienced “feeling[s] of being beyond help and 
without hope”).  
 179. See Isidoor O. Bergfeld et al., Treatment-Resistant Depression and Suicidality, 235 
J. AFFECTIVE DISORDERS 362, 362 (2018). 
 180. See, e.g., Celia B. Fisher et al., Ethical Issues in Including Suicidal Individuals in 
Clinical Research, IRB: ETHICS & HUM. RES., Sept.–Oct. 2002, at 9, 9–13. 
 181. See Bergfeld et al., supra note 179, at 362 (discussing the high rates of suicide 
attempts amongst treatment-resistant populations). 
 182. See Yanos et al., supra note 152, at 374. 
 183. Elise Stobbe, Resistance to Seeking Treatment for Mental Illness—How Others 
Can Help, BRAINBLOGGER (May 27, 2006), http://brainblogger.com/2006/05/27/anti-
stigmatization-resistance-to-seeking-treatment-for-mental-illness-how-others-can-help/ 
[http://perma.cc/82GT-9H48] (“More than any other reason, stigma, or fear of the 
consequences of being labeled ‘mentally ill’, prevents a person—who realizes he or she 
may need help—from reaching out for that help.”).  
 184. See Cody Brannan, Alexandra L. Foulkes & Gabriel Lázaro-Muñoz, Preventing 
Discrimination Based on Psychiatric Risk Biomarkers, 180B AM. J. MED. GENETICS 159, 
162 (2019).  
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possesses the information regarding a patient’s mental health has the 
power to misuse and mishandle the information and thereby has the 
power to potentially subject her patient to the stigma associated with 
the information’s improper publication. And so, to better understand 
the vulnerability of the population likely to be among the first to 
undergo CRISPR treatments in psychiatry, a good understanding of 
the evidence of mental health stigma and its implications is 
indispensable. 
Generally, stigma encompasses different elements of 
stereotyping, segregation, status loss, and discrimination.185 Numerous 
studies have established that mental health stigma is highly 
prevalent.186 Negative attitudes toward patients of psychiatry aren’t 
limited to the general lay population. Rather, negative attitudes are 
often widespread among clinicians themselves.187 Stigma often leads 
to discriminatory actions. For example, there is evidence that patients 
diagnosed with psychiatric conditions are being paid lower wages than 
their undiagnosed counterparts.188 Those diagnosed with psychiatric 
conditions also generally have lower chances of obtaining and 
keeping employment and receive subpar insurance benefits.189 
Further, those stigmatized often report being aware of the fact that 
society undervalues them and actively experience routine unfair 
treatment and avoidance by other people.190 It has also been 
suggested that those suffering from treatment-resistant conditions 
experience more severe stigma than other patients diagnosed with 
psychiatric conditions. 
Known stigma against those with treatment-resistant psychiatric 
disorders raises related concerns about privacy,191 especially in light of 
the fact that CRISPR interventions would likely require collecting 
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participants’ genetic information. Studies reveal significant public 
concerns about genetic privacy.192 Interestingly, people express 
greater concern about protecting the privacy of their mental health 
records than the privacy of their genetic information.193 Patients 
finding themselves involved in an intervention requiring both the 
disclosure of genetic information and mental health history should be 
considered especially vulnerable. In an effort to reduce further 
exposure to potentially hazardous stigma and its consequences, 
clinicians and researchers should take particular care to protect this 
population from improper disclosure and misuse of medical 
information, all while operating within a system that gives more 
protection to medical information in general.194 Scientists should 
likewise be aware of the fact that having genetic and mental health 
information at their disposal changes the power balance between 
themselves and the research subject. 
4.  Vulnerabilities Surrounding Decisionmaking Capacity 
Along with power-based vulnerabilities, patients first enrolled 
into CRISPR clinical trials in psychiatry may likely encounter 
vulnerabilities stemming from issues of informed consent. The 
decision to undergo a treatment using CRISPR is something that 
must be driven by the individual’s desire to eliminate certain 
symptoms and the consequences of these symptoms from the patient’s 
life. That is, as opposed to targeting a specific genetic profile 
generally.195 But what happens if—in the midst of complicated power 
dynamics and unwieldy risk assessments—the patient’s 
decisionmaking capacity is impaired? To what extent may treatment-
resistant populations be so affected by their cognitive impairments 
that they become unable to give meaningful informed consent? 
Available research tells us that the answer to these questions is far 
from clear. Nonetheless, there are reasons for ascribing safeguards to 
informed consent procedures involving treatment-resistant psychiatric 
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populations, especially for invasive and experimental interventions 
such as those involving CRISPR systems. 
While there is no bright-line rule for determining when an 
individual has decisionmaking capacity to consent to treatment or 
research interventions, several studies have documented the degree to 
which persons with psychiatric disorders are able to do so.196 Two 
notable conclusions can be drawn from this data. First, a majority of 
patients diagnosed with psychiatric disorders—particularly 
schizophrenia—have the decisionmaking capacity to provide 
informed consent.197 Second, researchers found that it is typical for a 
person diagnosed with a psychiatric disorder to have an 
understanding of the research that is subpar to the understanding of 
persons without psychiatric disorders.198 The recruitment source for 
the study and whether the protocol calls for inpatient or outpatient 
treatment impacts the proportion of participants who demonstrated 
capacity to provide informed consent.199 For example, a trial with 
long-term inpatients concluded that sixty-seven percent of persons 
with schizophrenia performed inadequately on tests of decisional 
impairment.200 But others found that only twenty percent to thirty 
percent of persons with schizophrenia from predominantly outpatient 
samples showed evidence of decisional impairment.201 
These findings suggest that although diminished capacity is an 
important consideration in regard to persons who have psychiatric 
disorders, it nevertheless is not universal or even typical. And 
therefore, it may be best to consider this vulnerability as likely to 
fluctuate with mental state. Determining how to gauge and act on the 
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likelihood of this vulnerability being present is an ethical issue 
CRISPR researchers will have to resolve. 
5.  Regulatory Treatment of Patients with Psychiatric Disorders as a 
Vulnerable Population 
Notwithstanding both the power-based and consent-based 
vulnerabilities we have identified above, there are currently no 
consistent federal or state regulations instituting prudent safeguards. 
Under the current guidelines from the DHHS, there are no special 
procedures guiding research involving persons diagnosed with 
psychiatric disorders of any severity. 
Regulations governing human subject research in the United 
States—when said research is either funded by or committed to the 
oversight of any of fifteen federal departments—are detailed in what 
is known as the Common Rule.202 The Common Rule is meant to 
codify the following principles, inter alia, and put them into practice: 
(1) respect for the autonomous decisionmaking of those capable of 
providing it and (2) providing protection for persons with diminished 
autonomy.203 As such, the Common Rule seeks to ensure voluntary 
participation in research through informed consent.204 In 2011, for the 
first time in a long time, DHHS set out to revise the Common Rule.205 
These revisions followed a call to the research committee, prompted 
by DHHS, for “information and comments about whether guidance 
or additional regulations are needed” for research involving people 
who have impaired decisionmaking capacity, such as people who have 
psychiatric disorders.206 A final rule was adopted in June 2018 and 
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took effect in January 2019.207 The final rule does not explicitly 
include those diagnosed with psychiatric disorders as a vulnerable 
population.208 Rather, the new Common Rule uses the phrase 
“individuals with impaired decision-making capacity” to replace the 
phrase “mentally disabled persons.”209 So, while DHHS’s guidebook 
for institutional review boards excludes mention of those diagnosed 
with psychiatric disorders from its instructions on procedures for 
research involving special classes of human subjects, it is possible 
these new regulations would encourage a different approach.210 
Guidance from states on what to do when decisionmaking abilities 
are insufficient so as to require additional safeguards is sparse and 
inconsistent.211 At times these guidelines are altogether absent.212 
Some institutional review boards already apply different 
standards to studies involving persons with psychiatric disorders.213 
And, outside of the research context, the medical community has 
included patients diagnosed with psychiatric conditions under the 
label of “vulnerable population.”214 Given the likely profile of 
patients to be first exposed to CRISPR research in psychiatry, 
safeguards for ensuring the protection of patients’ best interests 
should be firmly in place as a means of mitigating this population’s 
potential vulnerabilities. Again, the critiques of previous trials 
involving gene-editing technologies provide important insight. Critics 
of early trials explicitly called for an improvement to the way 
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clinicians obtain informed consent.215 The informed consent process, 
critics claimed, needs to be made as thorough as possible to safeguard 
the population of patients seeking gene-editing treatments.216 In this 
context, these safeguards must also include clear guidelines regarding 
who can serve as an appropriate surrogate decisionmaker when 
potential participants have insufficient decisionmaking capacity. 
In response to the lessons from history, regulatory bodies should 
aim for clarity and uniformity in their rules. But absent government 
action, the research community should nevertheless seek to take all 
steps necessary to protect treatment-resistant patients who are highly 
stigmatized and may lack decisionmaking capacity. These steps 
should include the introduction of safeguards into informed consent 
procedures and surrogate decisionmaking. 
B. General Ethical and Policy Issues Raised by CRISPR 
Applications in Psychiatry 
1.  Extinction 
Despite CRISPR’s therapeutic potential, technical issues 
surrounding CRISPR systems raise ethical concerns, chief among 
them being the potential for off-target effects.217 Off-target effects can 
be thought of as unintended mutations that result from the CRISPR 
intervention.218 Ethical concerns are especially poignant where the 
off-target effects involve the unintended mutation of the germline, 
meaning these unintended changes become heritable in humans.219 
In theory, the CRISPR alterations discussed in this Article would 
take place on somatic cells. A somatic cell modification is limited to 
the progeny of the original cell that developed the mutation and is not 
passable from parent to child.220 In contrast, a germline mutation is a 
mutation to the cells from which eggs and sperm are derived and 
through which genetic changes can be passed to the next 
generation.221 Thus, unlike genome editing of human germline cells, 
genome editing of human somatic cells aims to repair or eliminate 
 
 215. See supra Section I.C.  
 216. See supra Section I.C.  
 217. Xiang Jin Kang et al., Addressing Challenges in the Clinical Applications 
Associated with CRISPR/Cas9 Technology and Ethical Questions to Prevent Its Misuse, 8 
PROTEIN CELL 791, 792 (2017).  
 218. Id. 
 219. See id.  
 220. Kristine Krafts, Germline vs. Somatic Mutations, PATHOLOGY STUDENT (Aug. 22, 
2013), http://www.pathologystudent.com/?p=8539 [https://perma.cc/75QD-EWL6]. 
 221. Id. 
97 N.C. L. REV. 1359 (2019) 
1394 NORTH CAROLINA LAW REVIEW [Vol. 97 
pathogenic variants that cause disease only in that particular 
individual and not in his offspring.222 
But perhaps the theoretically sharp distinction between germline 
modification and somatic cell editing is somewhat idealistic. After all, 
early gene-therapy trials often saw unintended consequences 
impacting the germlines of research subjects, and early on, the FDA 
called for extreme caution when enrolling fertile patients into gene 
therapy studies.223 It is also possible that science may find a way to 
intentionally alter the germline to eradicate targeted conditions from 
future offspring. If this is in fact the case, CRISPR trials in psychiatry 
do have the potential to affect future generations. Scientists must 
consider the ethics of possibly eliminating genes associated with 
psychiatric conditions from future offspring’s genetic profiles. 
2.  Legal History, Eugenics, and Psychiatry 
Any discussion of extinction necessarily brings to mind the 
eugenics movement that flourished in America and elsewhere during 
the first part of the twentieth century and led to the implementation 
of a number of state statutes authorizing the sterilization of people 
affected by mental illness.224 Eugenics was founded on two core ideas: 
(1) the presumed hereditary influence of mental illness and (2) that 
people with mental illness had more children than the average 
person.225 It’s important to remember that great thinkers of the time 
saw eugenics as a legitimate and important public health movement, 
endorsed by most scientists working in the field of human genetics.226 
Ultimately, the effects of the eugenics movement on those with 
psychiatric disorders reverberated throughout the world, as eugenics 
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went on to form the core of Nazi doctrine.227 An estimated 300,000 
people were sterilized under Hitler’s Germany.228 Most of those 
targeted by sterilization laws were patients in mental health 
hospitals.229 Additionally, throughout the United States, courts upheld 
the constitutionality of states’ sterilization statutes, finding them 
“justified by the findings of biological science.”230 
But our legal system’s egregious treatment of those with 
psychiatric conditions is not a thing of the past. Today, “[t]he 
incidence of human rights violations in mental health care across 
nations has been described as .	.	. an ‘unresolved global crisis.’”231 In 
the United States over the last four decades, failed public policy, 
targeted budget cuts, and economic crises have had a 
disproportionate impact on those with serious psychiatric disorders.232 
As a consequence, those with psychiatric disorders have been 
relegated to an effective underclass, leaving those with untreated 
conditions cycling through psychiatric hospitals, civil courts, criminal 
courts, the streets, and correctional institutions.233 
Recently, the United States Supreme Court commented on a 
consequence of this subjugation in Brown v. Plata.234 In the case, 
plaintiffs in two class actions alleged Eighth Amendment violations 
based on the mistreatment of those affected by psychiatric disorders 
in state correctional institutions.235 In a poignant opinion, the Court—
speaking through Justice Kennedy—ordered California to drastically 
reduce its prison population.236 In doing so, Justice Kennedy noted 
that suffering and death had resulted from the shortcomings in mental 
health care and medical care for the mentally ill.237 Ironically 
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California’s legislative response to the decree made no mention of 
inmates with psychiatric disorders.238  
3.  Diversity 
Keeping in mind eugenics’ shameful history, in contemplating 
the use of CRISPR to treat psychiatric disorders, it is important to 
stress that an optimal therapy would target the behavior an individual 
has deemed disruptive and detrimental to his or her quality of life, as 
opposed to a specific genetic profile. CRISPR gene-editing therapy 
for an affected adult individual would not aim to eradicate a specific 
trait entirely from a population. After all, the broader goal of genetic 
cleansing would tread dangerously close to discrimination: the 
distinction between diversity and disability is not always clear.239 
With the completion of the Human Genome Project, scientists 
had at their disposal a “map [of] the human genetic terrain”—a 
standardized reference text.240 The purpose of genome sequencing 
was to identify defective genes and correct genetic mistakes.241 But 
the view of disability as a textual error—a “genetic other”—reinforces 
a negative construction of disabilities and undervalues genetic 
diversity.242 People without disabilities consistently underestimate the 
life satisfaction of the disabled.243 In fact, the difference in quality of 
life between the two groups is rather small, and a large proportion of 
people with serious disabilities describe their quality of life 
favorably.244 People also tend to overestimate how health impacts 
happiness, giving health more weight than other factors, including 
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economic stability or social support.245 Further, while in the United 
States psychiatric disorders are considered pathological and viewed as 
generally undesirable,246 the sentiment is not ubiquitous.247 Take for 
example the Belgian town of Geel, where strangers with mental 
illness have been embraced for centuries.248 In Geel, those with 
psychiatric disorders are called guests or boarders, as opposed to 
patients.249 Further, the attitudes of society shift over time as data is 
gathered and synthesized, and it is possible that what we consider a 
psychiatric disorder today may not be classified as such in the future. 
After all, homosexuality was once, in the not-so-distant past, 
categorized as a mental illness.250 
The goal of eradicating a specific trait entirely from a population 
also sounds a lot like the resurfacing of the eugenics movement.251 
CRISPR technologies could be used to guide human evolution, which 
was ultimately how some thinkers of the day conceptualized early 
eugenics.252 It is true that once the genetic composition that results in 
a phenotype is eradicated from within the individual’s germline cells, 
he or she will no longer be capable of passing that trait onto his or her 
offspring.253 For our purposes, however, the changes made in the 
DNA of an individuals’ somatic cells would not be heritable.254 Gene-
editing therapies developed from the application of CRISPR 
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technologies are ultimately unlike the insidious negative eugenics 
movement of our past in that the individual is free to reproduce and 
continue on their unmodified genetic line.255 The focus of gene-editing 
therapies, the individual’s genetic code, is different from the focus of 
the eugenics movement—altering the composition of the population 
at large.256 The former is focused on enhancing the well-being of an 
individual.257 The latter was centered on the future of the human race 
at the individual’s expense.258 
CONCLUSION 
Ample need exists for novel treatments in psychiatry, and 
CRISPR is an attractive candidate as a future solution. Most 
immediately, applications for treating monogenic diseases are likely. 
And because of the speed at which these technologies are evolving, 
coupled with the fact that CRISPR technologies are helping to 
further unravel the genetic architecture of more complicated diseases, 
additional applications in psychiatry are no longer highly improbable 
hypotheticals. The use of gene-editing technologies in the delicate 
realm of psychiatry, however, should take into consideration the harm 
in society’s binary view of disability as abnormal. Science and 
medicine, after all, are not value-free.259 And biomedical technologies 
participate in translating social agendas into technological ones.260 
 
 
 255. Id.  
 256. See Comfort, supra note 252 (“Eugenics is ‘the self-direction of human 
evolution.’”).  
 257. Matt Ridley, Foreword to DAVENPORT’S DREAM: 21ST CENTURY REFLECTIONS 
ON HEREDITY AND EUGENICS, at ix, xi (Jan A. Witkowski & John R. Inglis eds., 2008) 
(“One aims for individual happiness with no thought to the future of the human race; the 
other aims to improve the race at the expense of individual happiness.”).  
 258. Id.  
 259. SANDRA HARDING, WHOSE SCIENCE? WHOSE KNOWLEDGE?: THINKING FROM 
WOMEN’S LIVES 37 (1991) (“[T]he technologies used to produce scientific information are 
not value-neutral. For example, the development of the telescope moved authority about 
the patterns of the heavens from the church to the secular world and supported the 
emerging importance of the authority of individual observation. Contemporary scientific 
technologies .	.	. shift values in the sciences in other ways.”).  
 260. See id. at 37–38. 
